TRENDING TOPICS AND NEWS IN HCT AND CELLULAR THERAPY

Programmed cell death 1 (PD-1) ligands may be part of the challenge in applying chimeric antigen receptor (CAR) T-cell therapy to solid tumors but, researchers suspect, they also could be part of...

Study results indicate that cell therapy using B7 homolog 3 (B7-H3/CD276) may be a promising pathway in the pursuit of targeted therapies to treat ependymomas (EPNs).

Protection against graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (SCT) typically includes a calcineurin inhibitor plus an antimetabolic, but evidence supports adding...

Despite a lack of long-time evidence demonstrating the value of allogeneic hematopoietic cell transplantation (allo-HCT) in older adults with Philadelphia-positive acute lymphoblastic leukemia,...

Researchers believe that engineering chimeric antigen receptor (CAR) T cells to recognize CD155 is a novel approach that could be appropriate for both hematologic and solid tumors.

Fludarabine is valued for its role in chimeric antigen receptor (CAR) T-cell therapy, but scientists believe moving away from fixed dosages could mediate better outcomes.